ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ITOS iTeos Therapeutics Inc

16.23
-0.07 (-0.43%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
iTeos Therapeutics Inc NASDAQ:ITOS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.07 -0.43% 16.23 15.57 17.31 16.55 16.06 16.13 314,187 22:39:55

iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03/01/2024 12:00pm

GlobeNewswire Inc.


iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more iTeos Therapeutics Charts.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 10, 2024 at 3:00 p.m. PST (6:00 p.m. EST).

A live webcast of the presentation will be available on the Investors section of the Company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT:CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of Information

iTeos Therapeutics routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos Therapeutics.

For further information, please contact:

Investor Contact:

Carl MauchiTeos Therapeutics, Inc.carl.mauch@iteostherapeutics.com

Media Contact:

media@iteostherapeutics.com

1 Year iTeos Therapeutics Chart

1 Year iTeos Therapeutics Chart

1 Month iTeos Therapeutics Chart

1 Month iTeos Therapeutics Chart

Your Recent History

Delayed Upgrade Clock